What’s Up with the Biotech Rally?…Updates

http://idsn.com/wp-json/oembed/1.0/embed?url=http://idsn.com/faqs/ Update-1 1/20/19…XBI at $83.38 approaching November resistance at $85 Barron’s 2019 Roundtable biopharma picks: Abbvie (ABBV), Roche Holding (ROG), Gilead Sciences (GILD). ======= Biotech Rally Continues from the J.P.Morgan Healthcare Conference Slow and steady gains for biotech rally in 2019 Volatility and sentiment good for traders January effect after horrible December 2018 We appear to […]

Continue Reading 0

January 2019 Very Promising Wet Winter for the West: Storm and Climate… Update-1

purchase Lyrica from canada Update-1 1/15- 3:25 p Moderate to Heavy Rain through Wednesday Burn scarred areas near Malibu have mandatory evacuation because of floods and mud slides; PCH still open. Flash flood watch in Effect through 11 pm tonite; sunny weekend. ========= Wet Winter for the West: Major Storm Coming This Week According to some weather professionals these series […]

Continue Reading 0

2019 J.P.Morgan Conference Update: Healthcare Stocks Rally with Break-Outs…Updates

buy priligy priligy Update 1/14 After close: Biopharmas on the weak side from drug pricing politics. Both parties focused on pharmaceutical drug prices. IBB at $107.17 down 1.69% ; XBI at $80.12 down 2.29%. Red screen for Mid-Caps; BLUE BPMC NKTR all up a tad. Update 1/13 10:30P Sunday- With Futures Weak and Momentum Waning XBI at resistance $81.98 […]

Continue Reading 0

2019 J.P.Morgan Healthcare Notes #1 Panel: Reinventing the Disease Continuum Through Precision Health…Update

Update-1…1/21/19 Liquid Biopsy I attended a Panel Session on Cancer Liquid Biopsy and although progress is being made on molecular diagnostics there are no newsworthy breakthroughs nor actual data showing a hard timeline. Here is an article from  BIO 2016. There are over 70 genes that need to be tested and voluminous data is being generated […]

Continue Reading 0

Big Biopharma Bounce off Bottom: Mid Caps…Updates

1/7/19 …After Close: Most Mid-Caps held gains but check AH trading Selected Winners today: AGIO 8.7%, ALNY 8.75%, ARRY 8.85%, BLUE 6.67%, BPMC 14.1%, NKTR 7.83%, SGEN 5.68%, ICPT 7.28%, XBI 5.97% (closed at highs. $79.50). Many of these mid-caps are still at low end of 52 week range. Selected stocks above 52 week mid-range: […]

Continue Reading 0

Large Cap Biopharmaceutical Performance 2018…Updates BMY CELG, XBI

1/7/19 After Close: Both BMY and CELG held today up over 3%. ==== Stay tuned Next Week for Updates from the J.P.Morgan Healthcare Conference 1/5/19 Friday’s broad-based biopharmaceutical rally boosts stocks out of a “Bear Market”which brought the XBI down 25% off highs to the  $64 level on December 24, 2018 and now at $75. […]

Continue Reading 0

Free Falling Biotech Stocks Hit New 52 Week Lows…Updates 12/29

Update: 12/29/18 Biotech Stocks Halt Slide: IBB down 0.34% to $94.84 and up 4.7% for the week, XBI up 0.73% to $70.09 and up 5.6% for the week. XLV up 3.5% for the week to $85.25.Volatile market trying to hold DEC 24 bottom. Recent trades that worked: ABBV AMGN ; did not work ALXN CELG […]

Continue Reading 0

Bull Case for Biotech Remains Elusive-Trade Carefully…Update after FED Meeting

Update-2 After close: Market Collapses After FED Meeting-Bear Market  WE all knew that the biotech sector likes looser monetary policy but this sell-off is ridiculous. The IBB is now at May 2017 levels! XBI breaks through 2018 technicals down 3.33% on downside to $71.20, now at June 2017 lows. Update-1 1 pm 12/19/18 Green Day […]

Continue Reading 0

Trade Fears Derail Biotech Rally in a Jittery Market…Updates

Update -4 After Close 12/7/18 Market Performance for the Week XBI down 7.8%, IBB down 6.6%, XLV down 5.2%, QQQ down 5.11%. Futures not looking good at 12:40a EST, NAZ down 0.82%. Global Growth worries mount; geopolitical turmoil reigns. Moderna (MRNA) IPO closes down 19.13% to $18.60: Largest Biotech to Go Public…https://finance.yahoo.com/news/nasdaq-welcomes-moderna-inc-nasdaq-185435974.html ======= Update-3 After […]

Continue Reading 0

Trading the Biotech Bottom in 2018 in an Ambivalent Market…Updates ASH TSRO XBI

Update-2 December 3 …Our Top Pick TSRO is up 58% on GSK Buyout We recommended Tesaro (TSRO) at $34 and it paid off today with a ~$5.1B buyout by GlaxoSmith Kline! Year End Rally Intact with XBI up over 3% to $84 handle, ====== Update-1 December 1… NASDAQ Rallies 0.79% on Nov 30 Our recent […]

Continue Reading 0